Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT05000554 Recruiting - Gastric Cancer Clinical Trials

The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer

Start date: July 2, 2021
Phase: Phase 2
Study type: Interventional

To explore the safety and efficacy of local advanced stomach cancer patients receiving new complementary treatment of PD-1 monoantiotherapy before surgery

NCT ID: NCT04999332 Recruiting - Gastric Cancer Clinical Trials

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

LOTS
Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

NCT ID: NCT04989764 Completed - Clinical trials for Gastric Cancer, Outcomes, Pakistan, Adjuvant Chemotherapy, Perioperative Chemotherapy

COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER

Start date: January 2015
Phase:
Study type: Observational

- Patients with gastric adenocarcinoma - Comparison: perioperative chemotherapy vs. adjuvant therapy. - Sample size differences between the two groups. - Kaplan meier survival analysis, overall survival and disease free survival

NCT ID: NCT04989153 Recruiting - Gastric Cancer Clinical Trials

Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

Start date: March 5, 2016
Phase:
Study type: Observational [Patient Registry]

Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.

NCT ID: NCT04986085 Recruiting - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

NUTRIGETNE
Start date: February 24, 2021
Phase:
Study type: Observational

It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments. In patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET), due to their heterogeneity and longer survival, it is expected that the prevalence of malnutrition is probably underdiagnosed, as well as the existence of a negative impact on different parameters (quality of life, survival). So far, the studies carried out on nutrition and NET are very scarce and none has been carried out so far in Spain. Before being able to carry out nutritional intervention studies on these patients, it is necessary to know the reality of the nutritional status of patients with NETs in Spain. The main motivation for the NUTRIGETNE study is to evaluate the epidemiological status of nutrition in NETs in the spanish population. In addition to know the epidemiological picture, it is intended to study the nutritional status from different points of view: analytical, clinical, anthropometric, etc. Besides, the study of nutritional status will allow us to closely monitor the patients who have a higher risk of malnutrition and to propose early interventions for those, as well as the impact of their nutritional status on different parameters: survival, hospitalization, quality of life or responses to the treatments. NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status of patients with GEP NET in Spain will be evaluated.

NCT ID: NCT04985084 Completed - Stomach Neoplasms Clinical Trials

Development and Testing of a Social Cognitive Theory-based Dietary Behavioral Intervention in Gastric Cancer Survivors

Start date: January 12, 2022
Phase: N/A
Study type: Interventional

This study aims to develop a Social Cognitive Theory (SCT)-based dietary behavioral intervention for gastric cancer survivors, and explore the feasibility, acceptability, and preliminary effectiveness of delivering this intervention. This study includes two phases: intervention development in phase 1 and a pilot randomized controlled trial (RCT) in phase 2. During phase 1, the initial intervention protocol has been developed based on the SCT and literature review, which was further refined and/or enriched based on evidences from a qualitative descriptive study and an expert consultation. The qualitative descriptive study has been conducted from July to November 2021, and the expert consultation has been conducted from December 2021 to January 2022. For the qualitative descriptive study, purposive sampling was used to select eligible participants in patients who had a gastrectomy within two years from a tertiary hospital in Wuhan city, China. Three focus group interviews were performed with 13 participants via WeChat. Interviews were audio-recorded, transcribed verbatim, and analyzed using conventional qualitative content analysis. Data collection and analysis proceeded simultaneously until data saturation was reached. For the expert consultation, six experts majoring in nursing, digestive oncology, or nutrition were invited to assess the content validity of the intervention protocol. Data analysis of the qualitative descriptive study and the expert consultation is ongoing. During phase 2, the pilot RCT for testing the feasibility, acceptability, and preliminary effectiveness of the proposed intervention is started. All participants are recruited through convenience sampling from a tertiary hospital in Wuhan city, China. Sample size of the pilot RCT is proposed to be 72. After randomization, the participants are assigned to one of two groups, either the intervention group, which receive a 4-week dietary behavioral intervention; or the control group, which receive usual care only. The 4-week dietary behavioral intervention targets six dietary behaviors related to gastric cancer and is delivered by a registered nurse who has received around 32 hours of nutrition training. The intervention includes one session of face-to-face education and three sessions of telephone counselling; all sessions are individual based. The usual care is general dietary advice provided by the ward nurses before discharge. The general dietary advice is provided orally and printed in the discharge plan. The primary outcomes are feasibility and acceptability. The secondary outcomes include dietary consumption, quality of life, and self-efficacy. Outcome measurements are conducted at baseline (before randomization), and week 5 (after intervention). Generalized estimating equation model analyses will be conducted to examine group-by-time interaction effects.

NCT ID: NCT04982939 Recruiting - Gastric Cancer Clinical Trials

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Start date: June 21, 2021
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma

NCT ID: NCT04980950 Not yet recruiting - Colorectal Cancer Clinical Trials

"The Impact of Immunonutrition on Gut Microbiota-related Aspects in Colorectal Cancer and Gastric Cancer Patients"

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

Enteral immunomodulating nutrition modifies the gastrointestinal microbiota as well as improves the intestinal barrier integrity in patients with gastric and colorectal cancer in the perioperative period. As a consequence, it contributes to the reduction of the incidence of postoperative complications and diarrhea, which is a side effect of anti-cancer treatment often used preoperatively in this group of cancers.

NCT ID: NCT04977401 Terminated - Clinical trials for Early Gastric Cancer

EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection

EPSILON
Start date: September 21, 2021
Phase: N/A
Study type: Interventional

The EPSILON study aims to comparatively evaluate the submucosal injection using ORISETM gel and glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.

NCT ID: NCT04973631 Completed - Gastric Cancer Clinical Trials

The Effects of Sex and Age Differences on Gastric Cancer : a Retrospective Study

Start date: May 2003
Phase:
Study type: Observational

Gastric cancer (GC) is more prevalent in males than in females. One of these differences could be the effect of sex hormones such as estrogens. However, few reports have been reported regarding sex and age differences of incidence and survival of GC. The aim of this study was to evaluate the effect of sex and age on the incidence and survival of GC. And we would like to further analyze single GC and synchronous multiple GC, EBV, etc.